Johnson & Johnson Coronavirus vaccine illustration
Dado Ruvic | Reuters
Johnson & Johnson on Tuesday reported fourth-quarter earnings and income that beat Wall Road’s expectations.
This is how J&J did in contrast with what Wall Road anticipated, in line with common estimates compiled by Refinitiv:
- Adjusted EPS: $1.86 per share versus $1.82 anticipated.
- Income: $22.48 billion versus $21.67 billion anticipated.
“I am extremely pleased with our Johnson & Johnson groups around the globe for going above and past to fulfill stakeholder wants,” J&J CEO Alex Gorsky stated in a press launch. “We proceed to progress our COVID-19 vaccine candidate and stay up for sharing particulars from our Section 3 examine quickly.”
This can be a growing story. Please verify again for updates.